DUBLIN, Mar. 27, 2014
/PRNewswire/ --Research and Markets (http://www.researchandmarkets.com/research/x6dsmh/therapeutic_class) has announced the addition of the "Therapeutic Class Overview : Emergence of Biogenerics Era In Japan - It's Time to Welcome Antibody Biosimilars of Foreign Origins Soon" report to their offering.
With three products and eight players already in market - Japan biosimilar market will enter new phase of biosimilars with first mab' approval expected in 2014. This approval (Remicade- FY03/13A sales ¥73.5, infiximab from Nippon Kayaku by YE 14) will be marked as a milestone development because - 1.) it will open antibody biosimilar market in Japan, and 2.) the approval will be based largely from overseas data.
- ¥200b worth of biologic products is going off patent by 2015 and this value exceeds - ¥400b if it includes products that will see their patent expiries by 2021 in Japan (Table 1). There are number of reasons to believe that follow-on-biologics or biosimilars will not replicate the lethargic growth story of generic - preliminary because the much higher cost of biologic therapy brings significant burden on patients despite relatively low co-pay in Japan - and this will push individuals and DPC Hospitals to use biogeneric products to a greater extent unlike generic drugs. Secondly, the regulatory supports are going to be stringent enough to ensure quality measures and minimizing the not made in Japan' factor from prescriber's and user's mindsets.
Anticipating this opportunity and favorable macro forces as compared to generics, a number of companies aim to exploit this - Japan has seen a flood like consolidation and partnering activities in biosimilar space (Table 2, Annexure I).
Key Topics Covered:
EVOLVING BIOGENERIC LANDSCAPE IN JAPAN
INTENSIFIED COMPETITION IN FILGRASTIM BIOSIMILAR SPACE
REMICADE (INFLIXIMAB) BIOSIMILAR ENTRY EXPECTED IN CY 2014
JAPAN SPECIFIC HURDLES & DRIVERS
SELECT JAPANESE COMPANIES VENTURING INTO BIOGENERICS SPACE
For more information visit http://www.researchandmarkets.com/research/x6dsmh/therapeutic_clas
Media Contact: Laura Wood , +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets